Business Wire

NY-UNIFRAX

27.7.2021 13:02:06 CEST | Business Wire | Press release

Share
FlexCat™ by Unifrax Produces Increased Yield with Less Coking in Model PDH Study

Unifrax , a leading manufacturer of high-performance specialty materials, today announced initial results of the first phase of its testing campaign, performed at hte GmbH , leading provider of high throughput technology in catalysis research. These results support the ability of the recently launched FlexCat™ by Unifrax to significantly improve production throughput, increase process runtime and reduce a company’s carbon footprint.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210727005241/en/

FlexCat, a new customizable fiber-based catalyst support material, is designed for use in industrial catalysis, improving the output of hydrogen and specialty gas production, chemical processing, air purification and other chemical manufacturing applications.

Tested by hte GmbH, Unifrax targeted a model reaction of propane dehydrogenation (PDH) as a common industrial process and compared FlexCat to a literature derived and pellet-supported catalyst. Unifrax’s first step into industrial catalysis is a catalyst support material that has been proven to:

Provide enhanced yield and selectivity.

  • FlexCat increased output by 20 percent in the initial cycle and retained at least 90 percent conversion activity during the subsequent cycle tested.
  • This patented technology provided more tortuosity, maximizing catalyst interaction and producing 50 percent less side products per cycle, including four times less benzene.

Reduce production downtime.

  • FlexCat retained its conversion activity throughout the two cycles, offering up to 50 percent reduction in regeneration time and up to 12 percent longer run time.
  • FlexCat’s innovative product forms can be up to 10 times lighter than the conventional support being used, reducing loading and unloading time.

Allow for reduced downstream processing and cleaner outputs through plant optimization.

  • First lab scale data showed the potential of FlexCat to significantly reduce coking, improve conversion, and increase selectivity; addressing emissions concerns and providing a safer environment for employees and surrounding communities.

“In this latest round of testing, we homed in on specific areas where our industry partners strive to see improvements and derive value – from increased yield, reduced emissions and lower carbon footprints,” said Chad Cannan, senior vice president of research and development, Unifrax. “This next generation of catalysis technology will significantly increase production through existing assets and avoid costly capital expenditures and unnecessary downtime. This data shows that companies can realize greater value through their current production systems and improve their environmental footprint.”

“This collection of data, in partnership with hte GmbH, is a step in the right direction for industrial catalysis,” said John Dandolph, president and CEO, Unifrax. “With FlexCat, we’re working to optimize plant performance and the impact on local communities, focusing on a unique, game-changing solution. In confirming that we can increase output while reducing emissions and overall costs for our industry partners, we are excited to move forward with implementing this new technology to create better and more efficient catalysis that this industry has never seen before.”

With a track record of 75+ years developing and supplying engineered inorganic materials on a large scale to advanced industries worldwide, Unifrax has a deep history of fiber-based technology and manufacturing. As a first step into industrial catalysis for Unifrax, FlexCat offers a revolutionary fiber-based catalytic media that delivers more than the alumina-based catalysis technology used today.

“We look forward to continued collaboration with Unifrax on FlexCat,” said Wolfram Stichert, CEO, hte GmbH. “We’ve already seen promising results from our testing, and we can’t wait to see what’s ahead for this exciting and brand-new technology.”

Customizable for individual partners, processes and specific reactions, FlexCat can be manufactured at scale today. To learn more about FlexCat, visit www.unifrax.com/flexcat .

About Unifrax

Unifrax develops and manufactures high-performance specialty materials used in advanced applications, including high-temperature industrial insulation, electric vehicles, energy storage, filtration and fire protection, among many others. Unifrax products are designed with the ultimate goal of saving energy, reducing pollution and improving safety for people, buildings and equipment by delivering on our commitment to our customers of greener, cleaner, safer solutions for their application challenges. Unifrax has 37 manufacturing facilities operating in 12 countries and employs 2,700+ employees globally. More information is available at www.unifrax.com . For updates, follow us on Twitter , LinkedIn and Facebook .

About hte GmbH

At hte – the high throughput experimentation company, we make R&D in the area of catalysis faster and more productive. We enable cost-effective innovations and reduced time-to-market for new products, thereby allowing our customers in the energy & refining, chemical & petrochemical, and environmental industries to keep ahead of the competition. Our technology and services comprise:

  • R&D Solutions: highly efficient contract research programs at hte’s state-of-the-art laboratories in Heidelberg, Germany.
  • Technology Solutions: integrated hardware and software solutions, enabling our customers to establish high throughput workflows in their own laboratories.

Our customers benefit from broad technical and scientific expertise, exceptional customer orientation, complete end-to-end solutions, and outstanding data quality. Our close ties with BASF guarantee long-term orientation and stability.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye